The WashU Medicine Amyloid Center of Excellence has been selected as one of just 10 centers nationwide to participate in the American Heart Association’s ATTR-CM Discovery Initiative, a three-year program aimed at transforming care for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
The initiative brings together a select group of leading medical centers with the shared goal of understanding and improving the ATTR system of care, optimizing the patient pathway from initial identification through ongoing disease management.
As part of the initiative, the WashU Medicine team will work to identify and address current gaps in the ATTR patient journey, building toward a more streamlined and effective care experience. A key focus will be cultivating a network of diverse, multidisciplinary team members dedicated to establishing a comprehensive ATTR system of care.
ATTR-CM is a progressive and often underdiagnosed heart condition caused by the buildup of misfolded transthyretin proteins in the heart. Improved systems of care and earlier identification are critical to improving outcomes for the growing number of patients affected.
Read more about ATTR-CM here.